



UNIWERSYTET JAGIELLOŃSKI
W KRAKOWIE



C I T R U
Centrum Transferu Technologii

contact:

PhD Klaudia Polakowska – Technology Transfer Officer

Phone. +48 12 663 3832, +48 519 329 129, klaudia.polakowska@uj.edu.pl

**A NEW DRUG FOR THE PREVENTION AND TREATMENT OF HERPES
SIMPLEX VIRUS (HSV-1)
(TECHNOLOGY OFFER P-328)**

Potencial drug: *a modified dextran derivative*

Application: *prevention and treatment of herpes simplex virus (HSV-1)*

Herpes simplex virus 1 (HSV-1), is one of the most commonly encountered pathogens in humans. The most recent statistics indicate that approximately 50-90% of the world population is HSV-1 seropositive. The most common primary infections are cold sores occurring mainly on the face (especially the skin, tongue and lips). However, infection with HSV-1 may also lead to severe diseases such as inflammation of the eye or encephalitis. These diseases are characterized by severe course and may cause permanent adverse health effects (e.g. blindness), and even death.

Currently, there are several antiviral drugs, which are active against pathogens belonging to the *Herpesviridae* family. These drugs reduce the frequency and severity of relapses and also alleviate bothersome symptoms during the primary infection. Although they are usually only effective for the initial infection, they do not eliminate a virus in a latent state and thus do not protect a person before re-emergence of symptoms. There has also been increasing emergence of drug resistant viral strains. Thus, there is a need to find a new approach to developing effective treatment of HSV-1 infection. The **new invention of the Jagiellonian University**, which is the subject of the proposed offer, **discloses a new drug for treatment of herpes simplex virus (HSV-1) infection.**

ul Czapskich 4
31-110 Kraków
telefon: +48 12 663 38 30
www.citru.uj.edu.pl



UNIwersytet Jagielloński
w Krakowie

The main advantages of the offered drug are:

- ✓ confirmed ability to efficiently bind to herpes simplex virus (HSV-1) and inhibit its replication *in vitro*,
- ✓ low-toxicity of the drug *in vitro*,
- ✓ the possibility to apply as an ointment or solution administered either topically to the skin or eye, orally, intraperitoneally or intravenously.



CITTRU
Centrum Transferu Technologii

The offered invention is subject of a patent application. Further research and development are conducted at the Faculty of Chemistry and Faculty of Biochemistry, Biophysics and Biotechnology of the Jagiellonian University. Currently, the **Centre for Technology Transfer CITTRU** is looking for partners interested in the development of the invention and its commercial application.

More information:

PhD Klaudia Polakowska – Technology Transfer Officer

phone. +48 12 663 3832, +48 519 329 129, klaudia.polakowska@uj.edu.pl

ul Czapskich 4
31-110 Kraków
telefon: +48 12 663 38 30
www.cittru.uj.edu.pl